Objective 1: Extend the linear model to nonlinear and delayed-effect models
Objectiv 2: Automation of data preparation, model selection, and reporting
Objective 1: Extend the linear model to nonlinear and delayed-effect models
Objectiv 2: Automation of data preparation, model selection, and reporting
Develop an R package for design evaluation which can use Monolix or Simulx projects as input
Modern drug development, which can take up to 15 years and cost as much as $11 billion USD, relies heavily on high-quality data.
Modern drug development, which can take up to 15 years and cost as much as $11 billion USD, relies heavily on high-quality data1. Recognizing the criticality of attaining quality data that is easily convertible to analysis-ready datasets, a survey was developed to obtain baseline information on data quality and data standards, largely from a CRO perspective.
Non-small cell lung cancer (NSCLC) is a major cause of mortality in the United States[1].
While biologics offer promise in addressing a range of unmet medical needs, clinically observed BILI events are concerning for drug developers, health care providers and patients.
The development of generic ophthalmic drug products indicated for intraocular pressure (IOP) reduction typically relies on comparative pharmacodynamic (PD) endpoint bioequivalence (BE) studies.
Traditional toxicokinetic (TK) models rely heavily on in vivo data, necessitating animal testing. At the same time, the scientific toolbox is expanding with new approach methodologies (NAMs) that do not rely on TK studies.
Weight loss has positive effects on reducing hepatic lipid burden in MASH patients. Reports using various...
Otenaproxesul (ATB-346), a drug that combines naproxen with a thiobenzamide antioxidant, is being developed as an NSAID that reduces gut toxicity effects. Liver...
Infliximab (IFX), ipilimumab (IPI), and nivolumab (NIVO) have been associated with hepatotoxicity...
Immune checkpoint inhibitors (ICIs) have revolutionized treatment of various cancers. They act by releasing the brakes on immune responses to permit immune-mediated tumor cell killing...
The recent availability of effective GLP-1R agonist (GLP-1RA) based treatments of obesity has provided great benefit to patients. Understanding the balance between body weight (BW) loss...
As quantitative systems pharmacology (QSP) models are increasingly used to inform key...
Paroxysmal nocturnal hemoglobinuria (PNH) is one of multiple diseases in which complement dysregulation, leading to...
Metastatic, castration resistant prostate cancer (mCRPC) is an aggressive form of prostate cancer in...
The availability of effective GLP-1 receptor agonists (GLP-1RAs) for obesity treatment has greatly benefited patients. Balancing body weight (BW) loss with nausea is crucial to predict the effectiveness of these medications, along with understanding the impact of delivery methods. Quantitative Systems Pharmacology (QSP) modeling helps predict efficacy and adverse events, assessing key differences and similarities between treatment protocols.
The recent availability of effective, GLP-1R agonist (GLP-1RA) based treatments of obesity has provided...
Novel biomarkers have the potential to address early diagnosis and...
The recent availability of effective, GLP-1R agonist (GLP-1RA) based treatments of obesity has provided great benefit to patients